Role of the IL-1 Pathway in Dopaminergic Neurodegeneration and Decreased Voluntary Movement

Molecular Neurobiology

Volumn 54, Issue 6, 2017, Pages 4486-4495

  Stojakovic, Andrea ^a   Paz Filho, Gilberto ^b   Arcos Burgos, Mauricio ^b   Licinio, Julio ^c   Wong, Ma Li ^c   Mastronardi, Claudio A ^b,c  

^a LINKÖPING UNIVERSITY   (Sweden)

^b Australian National University   (Australia)

^c UNIVERSITY OF SOUTH AUSTRALIA   (Australia)

Author keywords

Dopaminergic neuron; Microglia; Open field; Rotarod; Substantia nigra

Indexed keywords

INTERLEUKIN 1; INTERLEUKIN 1 RECEPTOR BLOCKING AGENT; TYROSINE 3 MONOOXYGENASE;

ADULT; AGING; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CONTROLLED STUDY; DOPAMINERGIC NERVE CELL; IMMUNOHISTOCHEMISTRY; MICROGLIA; MIDDLE AGED; MOTOR DYSFUNCTION; MOTOR PERFORMANCE; MOUSE; NERVE DEGENERATION; NIGRONEOSTRIATAL SYSTEM; NONHUMAN; OPEN FIELD TEST; ROTAROD TEST; SIGNAL TRANSDUCTION; SUBSTANTIA NIGRA; WILD TYPE; YOUNG ADULT; ANIMAL; C57BL MOUSE; CELL COUNT; METABOLISM; MOTOR ACTIVITY; MOVEMENT (PHYSIOLOGY); PATHOLOGY; PATHOPHYSIOLOGY;

AGING; ANIMALS; CELL COUNT; DOPAMINERGIC NEURONS; INTERLEUKIN 1 RECEPTOR ANTAGONIST PROTEIN; INTERLEUKIN-1; MICE, INBRED C57BL; MICROGLIA; MOTOR ACTIVITY; MOVEMENT; NERVE DEGENERATION; ROTAROD PERFORMANCE TEST; SIGNAL TRANSDUCTION; SUBSTANTIA NIGRA; TYROSINE 3-MONOOXYGENASE;

EID: 84976433829     PISSN: 08937648     EISSN: 15591182     Source Type: Journal    
DOI: 10.1007/s12035-016-9988-x     Document Type: Article

References (52)

1. Nussbaum RL, Ellis CE (2003) Alzheimer’s Disease and Parkinson’s Disease. N Engl J Med 348(14):1356–64
2. Dauer W, Przedborski S (2003) Parkinson’s disease: mechanisms and models. Neuron 39(6):889–909
3. Block ML, Hong JS (2005) Microglia and inflammation-mediated neurodegeneration: multiple triggers with a common mechanism. Prog Neurobiol 76(2):77–98
4. Godbout JP et al (2005) Exaggerated neuroinflammation and sickness behavior in aged mice following activation of the peripheral innate immune system. FASEB J 19(10):1329–31
5. Dilger RN, Johnson RW (2008) Aging, microglial cell priming, and the discordant central inflammatory response to signals from the peripheral immune system. J Leukoc Biol 84(4):932–9
6. Collins LM et al (2012) Contributions of central and systemic inflammation to the pathophysiology of Parkinson’s disease. Neuropharmacology 62(7):2153–67
7. Dinarello CA (2011) A clinical perspective of IL-1β as the gatekeeper of inflammation. Eur J Immunol 41(5):1203–17
8. Kondo S et al (1995) Interleukin-1 receptor antagonist suppresses contact hypersensitivity. J Invest Dermatol 105(3):334–8
9. Li P et al (1995) Mice deficient in IL-1 beta-converting enzyme are defective in production of mature IL-1 beta and resistant to endotoxic shock. Cell 80(3):401–11
10. Hirsch E et al (1996) Functions of interleukin 1 receptor antagonist in gene knockout and overproducing mice. Proc Natl Acad Sci U S A 93(20):11008–13
11. Mastronardi C et al (2007) Caspase 1 deficiency reduces inflammation-induced brain transcription. Proc Natl Acad Sci U S A 104(17):7205–10
12. Kamens J et al (1995) Identification and characterization of ICH-2, a novel member of the interleukin-1 beta-converting enzyme family of cysteine proteases. J Biol Chem 270(25):15250–6
13. Craft JM et al (2005) Interleukin 1 receptor antagonist knockout mice show enhanced microglial activation and neuronal damage induced by intracerebroventricular infusion of human beta-amyloid. J Neuroinflammation 2:15
14. Herx LM, Rivest S, Yong VW (2000) Central nervous system-initiated inflammation and neurotrophism in trauma: IL-1 beta is required for the production of ciliary neurotrophic factor. J Immunol 165(4):2232–9
15. Depino A et al (2005) Differential effects of interleukin-1beta on neurotoxicity, cytokine induction and glial reaction in specific brain regions. J Neuroimmunol 168(1–2):96–110
16. Ferrari CC et al (2006) Progressive neurodegeneration and motor disabilities induced by chronic expression of IL-1beta in the substantia nigra. Neurobiol Dis 24(1):183–93
17. Carvey PM et al (2005) Intra-parenchymal injection of tumor necrosis factor-alpha and interleukin 1-beta produces dopamine neuron loss in the rat. J Neural Transm 112(5):601–12
18. McGeer PL, Itagaki S, McGeer EG (1988) Expression of the histocompatibility glycoprotein HLA-DR in neurological disease. Acta Neuropathol 76(6):550–7
19. Lawrence CB, Allan SM, Rothwell NJ (1998) Interleukin-1beta and the interleukin-1 receptor antagonist act in the striatum to modify excitotoxic brain damage in the rat. Eur J Neurosci 10(3):1188–95
20. Allan SM, Tyrrell PJ, Rothwell NJ (2005) Interleukin-1 and neuronal injury. Nat Rev Immunol 5(8):629–40
21. Liu Y et al (2008) Endotoxin induces a delayed loss of TH-IR neurons in substantia nigra and motor behavioral deficits. NeuroToxicology 29(5):864–70
22. Zhu BG et al (2012) Optimal dosages of fluoxetine in the treatment of hypoxic brain injury induced by 3-nitropropionic acid: implications for the adjunctive treatment of patients after acute ischemic stroke. CNS Neuroscience and Therapeutics 18(7):530–5
23. Yamada MH et al (2012) Impaired glycinergic synaptic transmission and enhanced inflammatory pain in mice with reduced expression of vesicular GABA transporter (VGAT). Mol Pharmacol 81(4):610–9
24. Kreutzfeldt M et al (2013) Neuroprotective intervention by interferon-γ blockade prevents CD8+ T cell–mediated dendrite and synapse loss. J Exp Med 210(10):2087–103
25. Kelly MA et al (1998) Locomotor activity in D2 dopamine receptor-deficient mice is determined by gene dosage, genetic background, and developmental adaptations. J Neurosci 18(9):3470–9
26. Vijitruth R et al (2006) Cyclooxygenase-2 mediates microglial activation and secondary dopaminergic cell death in the mouse MPTP model of Parkinson’s disease. J Neuroinflammation 3:6
27. Abdelsalam RM, Safar MM (2015) Neuroprotective effects of vildagliptin in rat rotenone Parkinson’s disease model: role of RAGE-NFkB and Nrf2-antioxidant signaling pathways. J Neurochem 133:700
28. Liu W et al (2015) Neuroprotective effects of lixisenatide and liraglutide in the 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine mouse model of Parkinson’s disease. Neuroscience 303:42–50
29. Lee J-Y et al (2009) Cytosolic labile zinc accumulation in degenerating dopaminergic neurons of mouse brain after MPTP treatment. Brain Res 1286:208–14
30. Yin F et al (2010) Exaggerated inflammation, impaired host defense, and neuropathology in progranulin-deficient mice. J Exp Med 207(1):117–28
31. McNeill TH, Koek LL (1990) Differential effects of advancing age on neurotransmitter cell loss in the substantia nigra and striatum of C57BL/6N mice. Brain Res 521(1–2):107–17
32. Deacon RM (2013) Measuring motor coordination in mice. J Vis Exp (75). doi: 10.3791/2609
33. Jones BJ, Roberts DJ (1968) The quantiative measurement of motor inco-ordination in naive mice using an acelerating rotarod. J Pharm Pharmacol 20(4):302–4
34. McGeer PL et al (1988) Reactive microglia are positive for HLA-DR in the substantia nigra of Parkinson’s and Alzheimer’s disease brains. Neurology 38(8):1285–91
35. McGeer PL et al (2003) Presence of reactive microglia in monkey substantia nigra years after 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine administration. Ann Neurol 54(5):599–604
36. Marinova-Mutafchieva L et al (2009) Relationship between microglial activation and dopaminergic neuronal loss in the substantia nigra: a time course study in a 6-hydroxydopamine model of Parkinson’s disease. J Neurochem 110(3):966–75
37. Gao L et al (2015) Infiltration of circulating myeloid cells through CD95L contributes to neurodegeneration in mice. J Exp Med 212(4):469–80
38. Tanaka S et al (2013) Activation of microglia induces symptoms of Parkinson’s disease in wild-type, but not in IL-1 knockout mice. J Neuroinflammation 10:143
39. Pott Godoy MC, Ferrari CC, Pitossi FJ (2010) Nigral neurodegeneration triggered by striatal AdIL-1 administration can be exacerbated by systemic IL-1 expression. J Neuroimmunol 222(1–2):29–39
40. Shaftel SS, Griffin WS, O’Banion MK (2008) The role of interleukin-1 in neuroinflammation and Alzheimer disease: an evolving perspective. J Neuroinflammation 5:7
41. Shaftel SS et al (2007) Chronic interleukin-1beta expression in mouse brain leads to leukocyte infiltration and neutrophil-independent blood brain barrier permeability without overt neurodegeneration. J Neurosci 27(35):9301–9
42. Hailer NP et al (2005) Interleukin-1beta exacerbates and interleukin-1 receptor antagonist attenuates neuronal injury and microglial activation after excitotoxic damage in organotypic hippocampal slice cultures. Eur J Neurosci 21(9):2347–60
43. Rothwell N (2003) Interleukin-1 and neuronal injury: mechanisms, modification, and therapeutic potential. Brain Behav Immun 17(3):152–7
44. Mastronardi CA et al (2015) Temporal gene expression in the hippocampus and peripheral organs to endotoxin-induced systemic inflammatory response in caspase-1-deficient mice. Neuroimmunomodulation 22(4):263–73
45. Fu SP et al (2015) Anti-inflammatory effects of BHBA in both in vivo and in vitro Parkinson’s disease models are mediated by GPR109A-dependent mechanisms. J Neuroinflammation 12(1):9
46. Nassar NN et al (2015) Saxagliptin: a novel antiparkinsonian approach. Neuropharmacology 89:308–17
47. Politis M, Lindvall O (2012) Clinical application of stem cell therapy in Parkinson’s disease. BMC Med 10:1
48. Gagne JJ, Power MC (2010) Anti-inflammatory drugs and risk of Parkinson disease: a meta-analysis. Neurology 74(12):995–1002
49. Tansey MG, Goldberg MS (2010) Neuroinflammation in Parkinson’s disease: its role in neuronal death and implications for therapeutic intervention. Neurobiol Dis 37(3):510–8
50. Luo L et al (2010) Ten years of Nature Reviews Neuroscience: insights from the highly cited. Nat Rev Neurosci 11(10):718–26
51. Horai R et al (2000) Development of chronic inflammatory arthropathy resembling rheumatoid arthritis in interleukin 1 receptor antagonist-deficient mice. J Exp Med 191(2):313–20
52. Kayagaki N et al (2011) Non-canonical inflammasome activation targets caspase-11. Nature 479(7371):117–21